Expertise in
3
conditions

Dr. Lynn J. Howie

Internal Medicine
Henderson County Hospital Corporation
805 6th Ave W Ste 100, 
Hendersonville, NC 
Clinical Trials:Currently Recruiting for 2 Trials
Accepting New Patients
17 Years of Experience
Expertise in
3
conditions
Henderson County Hospital Corporation
805 6th Ave W Ste 100, 
Hendersonville, NC 

Overview

Lynn Howie is a primary care provider, practicing in Internal Medicine in Hendersonville, North Carolina. She has been practicing medicine for over 17 years.

Dr. Howie is highly rated in 3 conditions, according to our data. Her clinical expertise encompasses Breast Cancer, Upper Tract Urothelial Carcinoma (UTUC), Familial Colorectal Cancer, and Colorectal Cancer.

She is actively involved in clinical research, co-authoring 21 peer reviewed articles and participating in 54 clinical trials. Dr. Howie is currently accepting new patients.

Graduate Year

2009

Specialties

Internal Medicine

Licenses

Internal Medicine in NC

Hospital Affiliations

Carteret General Hospital

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Friday Health

Accepted plan types not found. Please verify directly with the provider.

Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Oscar
  • EPO
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 2 Less Insurance Carriers -

Locations

Henderson County Hospital Corporation
805 6th Ave W Ste 100, Hendersonville, NC 28739

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

54 Clinical Trials

Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO (ACCIO)
Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO (ACCIO)
Enrollment Status: Recruiting
Publish Date: September 08, 2026
Intervention Type: Procedure, Drug, Other, Biological
Study Drugs: Carboplatin, Cisplatin, Gemcitabine Hydrochloride, Paclitaxel, Pembrolizumab, Pemetrexed Disodium
Study Phase: Phase 3
A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC)
A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC)
Enrollment Status: Recruiting
Publish Date: September 08, 2026
Intervention Type: Procedure, Biological, Drug
Study Drugs: Cabozantinib, Ipilimumab, Nivolumab
Study Phase: Phase 2
Randomized Phase III Trial of MEDI4736 (Durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC
Randomized Phase III Trial of MEDI4736 (Durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC
Enrollment Status: Active_not_recruiting
Publish Date: September 08, 2026
Intervention Type: Drug, Biological
Study Drugs: Carboplatin, Cisplatin, Durvalumab, Etoposide, Paclitaxel, Pemetrexed Disodium
Study Phase: Phase 3
Colorectal Cancer Metastatic dMMR/MSI-H Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab/Atezolizumab Combination Versus Single Agent Atezolizumab in the First-Line Treatment of Patients With Deficient DNA Mismatch Repair (dMMR)/Microsatellite Instability-High (MSI-H) Metastatic Colorectal Cancer
Colorectal Cancer Metastatic dMMR/MSI-H Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab/Atezolizumab Combination Versus Single Agent Atezolizumab in the First-Line Treatment of Patients With Deficient DNA Mismatch Repair (dMMR)/Microsatellite Instability-High (MSI-H) Metastatic Colorectal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 08, 2026
Intervention Type: Other, Procedure, Drug, Biological
Study Phase: Phase 3
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
Enrollment Status: Terminated
Publish Date: September 04, 2026
Intervention Type: Other, Drug
Study Drug: Aspirin
Study Phase: Phase 3
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women With Early Breast Cancer
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women With Early Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 02, 2026
Intervention Type: Other
Study Phase: Phase 3
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: August 31, 2026
Intervention Type: Other, Radiation, Procedure, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 3
A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: August 31, 2026
Intervention Type: Radiation, Procedure
Study Phase: Phase 3
PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib With Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE]
PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib With Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE]
Enrollment Status: Active_not_recruiting
Publish Date: August 31, 2026
Intervention Type: Other, Procedure, Drug, Biological
Study Drugs: Cabozantinib, Ipilimumab, Nivolumab
Study Phase: Phase 3
DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) a Phase III Trial
DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) a Phase III Trial
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Procedure, Biological, Drug
Study Drugs: Dabrafenib Mesylate, Ipilimumab, Nivolumab, Trametinib Dimethyl Sulfoxide
Study Phase: Phase 3
View 8 Less Clinical Trials

21 Total Publications

Perspectives on Patient-Reported Outcome Data After Treatment Discontinuation in Cancer Clinical Trials.
Perspectives on Patient-Reported Outcome Data After Treatment Discontinuation in Cancer Clinical Trials.
Journal: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
Published: February 22, 2023
Similar Doctors
Expertise in
81
conditions
Dr. Blair L. Holl
Internal Medicine
Expertise in
81
conditions
Dr. Blair L. Holl
Internal Medicine

Office

90 Southside Ave Ste 350, 
Asheville, NC 
 (22.8 miles away)
828-277-4810
Languages Spoken:
English
See accepted insurances

Blair Holl is a primary care provider, practicing in Internal Medicine in Asheville, North Carolina. Dr. Holl is highly rated in 81 conditions, according to our data. His clinical expertise encompasses Low Blood Pressure, Familial Chronic Mucocutaneous Candidiasis, Anemia, and Thrush.

Expertise in
28
conditions
Dr. Gregory L. Glance
Internal Medicine
Expertise in
28
conditions
Dr. Gregory L. Glance
Internal Medicine
Before you request

Kerr Drug Acquisition Inc

275 McDowell St, 
Asheville, NC 
 (22.0 miles away)
828-258-0397
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Gregory Glance is a primary care provider, practicing in Internal Medicine in Asheville, North Carolina. Dr. Glance is highly rated in 28 conditions, according to our data. His clinical expertise encompasses Cirrhosis, Xanthoma, Familial Combined Hyperlipidemia, and High Cholesterol. Dr. Glance is currently accepting new patients.

Expertise in
51
conditions
Dr. Victoria A. Arlauskas
Internal Medicine
Expertise in
51
conditions
Dr. Victoria A. Arlauskas
Internal Medicine
Before you request

Medical Group Of The Carolinas-Internal Medicine-Westside

8311 Warren H Abernathy Hwy, 
Spartanburg, SC 
 (37.2 miles away)
864-560-9435
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Victoria Arlauskas is a primary care provider, practicing in Internal Medicine in Spartanburg, South Carolina. Dr. Arlauskas is highly rated in 51 conditions, according to our data. Her clinical expertise encompasses High Cholesterol, Hypertension, Glucocorticoid-Remediable Aldosteronism, and Familial Hypertension. Dr. Arlauskas is currently accepting new patients.

Frequently Asked Questions about Dr. Lynn J. Howie

How do I make an appointment with Dr. Lynn J. Howie?

You can book an appointment with Dr. Lynn J. Howie by calling their office at 828-692-8045. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Lynn J. Howie a top-rated expert for Breast Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Lynn J. Howie is classified as an Distinguished expert for Breast Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Lynn J. Howie specialize in?

While Dr. Lynn J. Howie is a Internal Medicine, they have specific expertise in Breast Cancer, Upper Tract Urothelial Carcinoma (UTUC), and Familial Colorectal Cancer. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Internal Medicine.

Does Dr. Lynn J. Howie participate in research or clinical trials?

Yes. Dr. Lynn J. Howie has published 21 articles and abstracts on conditions like Breast Cancer. You can view a list of Dr. Lynn J. Howie's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Lynn J. Howie accept my insurance?

Dr. Lynn J. Howie accepts most major insurance plans, including Aetna and Blue Cross Blue Shield. We recommend calling the office directly at 828-692-8045 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Howie's expertise for a condition
ConditionClose
    View All 58 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile